Zarix Initiates U.S.-To-Europe Strategy With Agouron Thymitaq Deal
Executive Summary
The Irish biopharmaceutical firm Zarix will develop Agouron's oncologic agent Thymitaq (nolatrexed) worldwide as the first step in its strategy of introducing U.S. biotech products to European markets.